1. Enhanced spiral ganglion neuron transduction for neurotrophin gene therapy with novel capsid-engineered AAV vector.
- Author
-
Marx, J., Huang, P., Sutter, S., Ertelt, M., Kaiser, O., Harre, J., Bon Nieves, A., Schott, J., Macdonald, J., Rossi, A., Warnecke, A., Schoeder, C. T., Schambach, A., Staecker, H., and Büning, H.
- Subjects
PROTEINS ,GENE therapy ,NEURONS ,CONFERENCES & conventions ,SPIRAL ganglion ,NERVE growth factor ,VIRUSES - Abstract
Hearing loss (HL) affects over 460 million people worldwide, significantly affecting quality of life. Genetic analysis has identified more than 150 causative monogenic genes for non-syndromic sensorineural hearing loss, presenting attractive targets for gene therapy interventions. These approaches also have the potential to enhance conventional treatment strategies. Particularly interesting in this regard are cochlear implants (CI), used for severe to profound HL. However, their efficacy is believed to depend on spiral ganglion neuron (SGN) survival. Recognizing the potential of neurotrophins to enhance SGN survival and improve CI outcomes, we here report on the development of a novel adeno-associated virus (AAV) vector optimized for transducing SGN, even in adult mice and at low vector doses. For this purpose, the capsid was engineered to display a heptamer peptide, which was previously derived from a phage library screen. Structure-focused modeling of our novel vector Var9 indicated a clear change in cell attachment receptor binding due to peptide insertion compared to its parental serotype AAV2. Predictions were confirmed using affinity chromatography and competition assays. Interestingly, Var9 demonstrated faster transgene expression in HEI-OC1 cells, a murine otic progenitor cell line, despite significantly lower entry efficiency, indicating enhanced intracellular processing of the vector. Subsequent IF-FISH analysis at single-cell level as well as our indirect uncoating assay revealed that Var9 vectors clearly outperform AAV2 vectors regarding kinetics and level of uncoating (3-fold), i.e. release of their genome from the capsid, a prerequisite for transgene transcription. Finally, in a neurotrophic gene therapy approach, Var9 effectively prevented SGN degeneration by overexpressing BDNF in SGN of deafened mice. Histological analysis of the cochlea revealed remarkable protective effects of SGN comparable to untreated control levels in all cochlear turns of mice treated with Var9-BDNF. In conclusion, our novel AAV vector demonstrated superior properties crucial for efficient SGN transduction and will be further refined for clinical applications, aiming to enhance neural survival and improve outcomes for cochlear gene therapy in CI recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2024